Skip to main content

Table 11 Concomitant medication use by adjudicated AOE and serious AOE status

From: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

  Total (n = 449) No AOE (n = 371) Any AOE (n = 78) Serious AOE (n = 74)
Baseline concomitant medications
 Antihypertensives 86 (19) 63 (17) 23 (29) 22 (30)
 Acetylsalicylic acid 39 (9) 23 (6) 16 (21) 15 (20)
 Platelet aggregation inhibitors 38 (8) 22 (6) 16 (21) 15 (20)
 Anti-diabetic agents 24 (5) 13 (4) 11 (14) 10 (14)
 Lipid-modifying agents 22 (5) 16 (4) 6 (8) 6 (8)
 Anticoagulants 15 (3) 13 (4) 2 (3) 2 (3)
Concomitant medication use at any time
 Antihypertensives 233 (52) 181 (49) 52 (67) 50 (68)
 Acetylsalicylic acid 125 (28) 92 (25) 33 (42) 33 (45)
 Platelet aggregation inhibitors 122 (27) 85 (23) 37 (47) 37 (50)
 Anticoagulants 58 (13) 50 (13) 8 (10) 8 (11)
 Lipid-modifying agents 51(11) 39 (11) 12 (15) 12 (16)
 Anti-diabetic agents 45 (10) 26 (7) 19 (24) 18 (24)
  1. Data are no. (%) of patients
  2. AOE arterial occlusive event